A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 13th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 464 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 51st largest by enrollment of the 170 interventional ones that give a count, is one of 6 that started in 2014, is one of 86 in phase 3, and was the 159th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin. The primary objective of the trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides greater reduction in A1C compared with the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses of ertugliflozin.
The duration of the trial will be approximately 69 weeks. This will include a 1-week Screening Period, an up to 12-week wash-off/titration /dose-stabilization period, a 2-week single-blind, placebo run-in period, a 52-week double-blind, placebo-controlled treatment period (including a 26-week Phase A and 26-week Phase B), and a post-treatment telephone contact 14 days after the last dose of blinded investigational product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin, 5 mg, oral, once daily for 52 weeks
Drug: Ertugliflozin 5 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin · Drug: Placebo for ertugliflozin 10 mg
Ertugliflozin, 15 mg, oral, once daily for 52 weeks
Drug: Ertugliflozin 15 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin
Matching placebo to ertuglifozin, oral, once daily for 52 weeks
Drug: Placebo for ertugliflozin 5 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin · Drug: Placebo for ertugliflozin 10 mg
Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
Also known as: MK-8835, PF-04971729
Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
Also known as: MK-8835, PF-04971729
Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
Also known as: Glucophage, Glucophage XR
Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
Also known as: JANUVIA®
Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
Also known as: AMARYL
Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
Change From Baseline in Hemoglobin A1C at Week 26
A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Experiencing An Adverse Event (AE)
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
Time frame: Up to Week 54
Percentage of Participants Discontinuing Study Treatment Due to an AE
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
Time frame: Up to Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight at Week 26
The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Week 26
Change From Baseline in Sitting Systolic Blood Pressure at Week 26
The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Hemoglobin A1C at Week 52
A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in FPG at Week 52
The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in Body Weight at Week 52
The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Week 52
Change From Baseline in Sitting Systolic Blood Pressure at Week 52
The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26
The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Sitting Diastolic Blood Pressure at Week 52
The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Percentage of Participants Receiving Glycemic Rescue Medication by Week 26
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).
Time frame: Week 26
Percentage of Participants Receiving Glycemic Rescue Medication by Week 52
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).
Time frame: Week 52
Time to Initiation of Glycemic Rescue by Week 26
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.
Time frame: Up to Week 26 (plus 30 days for 1 placebo participant)
Time to Initiation of Glycemic Rescue by Week 52
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.
Time frame: Up to week 52
Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]
Time frame: Baseline
Change From Baseline in HOMA-%β at Week 26
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in HOMA-%β at Week 52
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).
Time frame: Baseline
Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in EQ-5D-3L Score at Week 52
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 52
| Milestone | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Started | 156 | 155 | 153 |
| Treated | 156 | 153 | 153 |
| Completed | 151 | 143 | 139 |
| Not completed | 5 | 12 | 14 |
| Withdrew: Adverse event | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 2 |
| Withdrew: Screen failure | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 9 |
| Withdrew: Hyperglycemia | 0 | 0 | 1 |
A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percent | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 26 | -0.78 (-0.91 to -0.65) | -0.86 (-0.99 to -0.72) | -0.09 (-0.23 to -0.04) |
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) | 57.7 | 60.1 | 63.4 |
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE | 4.5 | 3.9 | 3.9 |
The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | -26.91 ± -32.58 | -33.04 (-38.71 to -27.36) | -1.76 (-7.70 to 4.18) |
The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
| kg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | -3.35 (-3.78 to -2.91) | -3.04 (-3.48 to -2.60) | -1.32 (-1.77 to -0.87) |
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26 | 32.1 | 39.9 | 17.0 |
The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline | 130.87 ± 0.62 | 130.87 ± 0.62 | 130.87 ± 0.62 |
| Change from baseline | -3.81 ± 0.87 | -4.82 ± 0.88 | -0.88 ± 0.93 |
A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percent | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 52 | -0.75 (-0.90 to -0.59) | -0.81 (-0.97 to -0.66) | 0.02 (-0.15 to 0.19) |
The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in FPG at Week 52 | -25.57 (-30.91 to -20.23) | -26.38 (-31.80 to -20.97) | 3.19 (-3.08 to 9.47) |
The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
| kg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 | -3.46 (-4.07 to -2.85) | -2.83 (-3.45 to -2.21) | -0.95 (-1.65 to -0.26) |
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52 | 33.3 | 32.7 | 13.7 |
The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline | 130.92 ± 0.62 | 130.92 ± 0.62 | 130.92 ± 0.62 |
| Change from baseline | -4.16 ± 0.95 | -4.09 ± 0.96 | 0.83 ± 1.14 |
The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline | 78.42 ± 0.36 | 78.42 ± 0.36 | 78.42 ± 0.36 |
| Change from baseline | -1.68 ± 0.61 | -1.81 ± 0.62 | -0.43 ± 0.65 |
The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline | 78.44 ± 0.36 | 78.44 ± 0.36 | 78.44 ± 0.36 |
| Change from baseline | -1.52 ± 0.61 | -1.38 ± 0.62 | -0.53 ± 0.73 |
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Receiving Glycemic Rescue Medication by Week 26 | 1.3 | 2.0 | 16.3 |
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Receiving Glycemic Rescue Medication by Week 52 | 12.8 | 13.7 | 41.8 |
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.
| Days | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Minimum time to initiation of glycemic rescue | 135 | 43 | 26 |
| Maximum time to initiation of glycemic rescue | 141 | 147 | 212 |
Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.
| Days | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Minimum time to initiation of glycemic rescue | 135 | 43 | 26 |
| Maximum time to initiation of glycemic rescue | 295 | 299 | 327 |
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]
| Percentage | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value | 47.99 ± 23.890 | 48.54 ± 34.782 | 48.04 ± 30.733 |
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.
| Percentage | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in HOMA-%β at Week 26 | 13.28 (8.87 to 17.68) | 12.43 (7.94 to 16.93) | 0.52 (-4.08 to 5.12) |
HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.
| Percentage | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in HOMA-%β at Week 52 | 10.85 (6.29 to 15.41) | 10.93 (6.24 to 15.61) | -1.93 (-6.88 to 3.02) |
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).
| Score on a scale | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score | 0.88 ± 0.166 | 0.89 ± 0.182 | 0.90 ± 0.144 |
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.
| Score on a scale | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26 | 0.00 (-0.02 to 0.03) | 0.02 (-0.00 to 0.04) | 0.01 (-0.01 to 0.04) |
The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.
| Score on a scale | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in EQ-5D-3L Score at Week 52 | 0.03 (-0.00 to 0.05) | -0.00 (-0.03 to 0.03) | 0.02 (-0.01 to 0.06) |
Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg (Phase A+B) | — | 13/156 (8.3%) | 24/156 (15.4%) |
| Ertugliflozin 15 mg (Phase A+B) | — | 3/153 (2%) | 18/153 (11.8%) |
| Placebo (Phase A+B) | — | 8/153 (5.2%) | 29/153 (19%) |
| Event | Ertugliflozin 5 mg (Phase A+B) | Ertugliflozin 15 mg (Phase A+B) | Placebo (Phase A+B) |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/156 | 0/153 | 1/153 |
| Abdominal pain lowerGastrointestinal disorders | 0/156 | 0/153 | 1/153 |
| Non-cardiac chest painGeneral disorders | 0/156 | 0/153 | 1/153 |
| CholelithiasisHepatobiliary disorders | 0/156 | 0/153 | 1/153 |
| Liver disorderHepatobiliary disorders | 0/156 | 1/153 | 0/153 |
| Bone tuberculosisInfections and infestations | 0/156 | 0/153 | 1/153 |
| Meningitis tuberculousInfections and infestations | 0/156 | 0/153 | 1/153 |
| Subcutaneous abscessInfections and infestations | 0/156 | 0/153 | 1/153 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 0/153 | 1/153 |
| Cerebral haemorrhageNervous system disorders | 0/156 | 1/153 | 0/153 |
| Event | Ertugliflozin 5 mg (Phase A+B) | Ertugliflozin 15 mg (Phase A+B) | Placebo (Phase A+B) |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 7/156 | 5/153 | 11/153 |
| Urinary tract infectionInfections and infestations | 2/156 | 5/153 | 8/153 |
| NasopharyngitisInfections and infestations | 8/156 | 6/153 | 5/153 |
| Back painMusculoskeletal and connective tissue disorders | 8/156 | 3/153 | 6/153 |
All participants as treated population excludes two participants randomized to Ertugliflozin 15 mg but did not receive any treatment.
| Age, Continuous(Years) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.2 ± 9.3 | 59.7 ± 8.6 | 58.3 ± 9.2 | 59.1 ± 9.0 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 75 | 71 | 53 | 199 |
| Male | 81 | 82 | 100 | 263 |
| Hemoglobin A1c (A1C)(Percent) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.05 ± 0.86 | 8.00 ± 0.83 | 8.03 ± 0.93 | 8.03 ± 0.88 |
| Fasting plasma glucose(mg/dL) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 167.7 ± 37.7 | 171.7 ± 39.1 | 169.6 ± 37.8 | 169.7 ± 38.2 |
| Body weight(Kilograms) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 87.6 ± 18.6 | 86.6 ± 19.5 | 86.4 ± 20.8 | 86.9 ± 19.6 |
| Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 87.0 ± 17.5 | 86.9 ± 15.6 | 89.9 ± 17.5 | 87.9 ± 16.9 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2014 to primary completion in Jun 2016, 26 months.
Results were first posted in Jul 2017, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin